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Abstract
Recommendations for the initiation of combination antiretroviral therapy in HIV-positive individuals
are largely based on data from observational studies. Whilst all guidelines recommend immediate
treatment in individuals with a CD4 count of less than 350 cells/mm
3, guidelines vary in their
recommendations for treatment at higher CD4 counts. Several large cohort studies have published
findings that contribute to the debate, although conclusions vary and results from these studies may
be subject to bias.
Introduction and context
In resource-rich settings, treatment guidelines are consis-
tent in recommending the immediate initiation of com-
bination antiretroviral therapy (cART) in all HIV-positive
individuals with a CD4 count of less than 350 cells/mm
3;
in this group, the benefits of cART clearly outweigh its
disadvantages. However, there is inconsistency between
the guideline committees as to whether asymptomatic
individuals with CD4 counts equal to or greater than
350 cells/mm
3 should begin cART. For example, whilst
the 2009 US Department of Health and Human Services
guidelines [1] and the International AIDS Society-USA [2]
panel recommend treatment for all patients with a CD4
count of 350-500 cells/mm
3, neither the European AIDS
Clinical Society [3] nor the British HIV Association [4]
recommends treatment at this level unless specific com-
orbidities are present. This inconsistency largely results
from the limited evidence base; as only limited data are
available from randomized trials on the benefits or risks
of earlier cART [5], guideline committees have based their
recommendationsonevidencefromobservationalstudies
and expert clinical opinion.
Until recently, the main arguments for delaying cART
related to the toxicities and inconvenience of the drugs,
as well as the concern that patients would be unable to
maintain the high levels of adherence necessary to ensure
sustained virological suppression. Little was felt to be
gained from initiating cART in individuals with CD4
counts of greater than 350 cells/mm
3 in whom the risk
of AIDS and consequent mortality was low. However,
antiretroviral drugs are now more potent, have fewer
toxicities, and are more forgiving to lapses in adherence.
Furthermore, death rates in HIV-positive individuals
remain elevated compared to those in the general
population [6,7] and it is believed that HIV may play a
role in the development of several serious non-AIDS
conditions [8-10]. Thus, cART may have a greater posi-
tive impact on the health of HIV-positive individuals
than anticipated, which may now justify its earlier use.
This review briefly summarises the latest evidence on the
topic; recent reviews discuss some of the issues in more
detail [11,12].
Recent advances
Many observational studies have compared outcomes
amongindividualsinitiatingcARTat differentCD4counts
[13,14]. However, an individual who is not diagnosed
with HIV until his/her CD4 count has fallen to a low level
could not have received treatment at a higher CD4 count
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long enough to be diagnosed at the lower CD4 count.
Failure to take account of this ‘lead-time’ may result in
biased estimates of the benefits of early treatment [15].
Conclusions from early studies that used appropriate
methodology to remove the effect of lead-time bias were
inconsistent regarding the initiation of cART at a CD4
count of greater than 350 cells/mm
3 [16,17]. However,
these studies were relatively small, and the methods may
not have been optimal.
Investigators from the North American AIDS Cohort
Collaboration on Research and Design (NA-ACCORD)
study [18] identified individuals who had experienced a
CD4 count of either 351-500 cells/mm
3 or greater than
500 cells/mm
3; these groups were then divided again
into those who initiated cART immediately and those
who deferred its use. The authors used inverse prob-
ability weighting methods to control for biases resulting
from informative censoring (which may arise if patients
who dropped out of the analysis at any stage had
different characteristics to those who did not) and
known confounders. Of the 67,527 patients in the
study, 8362 had a CD4 count of 351-500 cells/mm
3
(2084 initiated cART immediately) and 9155 a CD4
count of greater than 500 cells/mm
3 (2220 initiated
cART immediately). Death rates were increased by 69%
and 94%, respectively, among those who deferred
therapy in each group compared to those who started
cART immediately. Investigators from the When to Start
Consortium [19] considered progression to AIDS and/or
death in 24,444 antiretroviral-naive individuals starting
cART. Using information from 21,247 patients followed
in the pre-cART era, the authors estimated the distribu-
tion of lead-times, which was then incorporated into the
analysis. Deferred initiation of cART was generally
associated with more rapid progression rates than
immediate initiation, although the difference was not
statistically significant at CD4 counts of greater than
350 cells/mm
3.Shepherd et al. [20] directly estimated the
optimal CD4 count at which to initiate cART. Using a
similar method to the NA-ACCORD group, they
concluded that the optimal CD4 count depended on
whether the ultimate aim of cART was to improve the
patient’s health (defined by an increase in the CD4 count
or reduction in the occurrence of new AIDS events or
death), in which case the threshold was between 489 and
554 cells/mm
3, or to improve quality-of-life, in which
case the threshold was between 337 and 475 cells/mm
3.
Most recently, Jonsson Funk et al. [21] presented data
from the CASCADE Collaboration [21] suggesting that
whilst the initiation of cART at a CD4 count of 350-500
cells/mm
3 may reduce the risk of clinical progression, the
low absolute risk of progression meant that 34 patients
would need to be treated to prevent one new case of
AIDS or death (or 71 patients for death only) over a
three-year period.
As an alternative approach, several authors have used
computer simulation models to address the issue.
Mauskopf et al. [22] estimated that initiation of cART at
aCD4countofgreaterthan350cells/mm
3wouldresultin
longer quality-adjusted survival compared to starting
cART at lower CD4 counts. Braithwaite et al. [23] demon-
strated that treatment at a CD4 count of 500 cells/mm
3
resulted in gains in quality-adjusted life-years at all ages,
even assuming that patients may not be fully adherent to
cART. The validity of results from modelling studies does,
however, rely strongly on the assumption that the model
accurately describes disease progression.
Implications for clinical practice
Whilst the accruing evidence would suggest that earlier
initiation of cART may be beneficial, one limitation of all
observational studies is that of unmeasured confound-
ing. Under most treatment guidelines, few patients
initiate cART at high CD4 counts and those who do
may differ from those who do not in terms of their likely
long-term outcomes, regardless of cART use. It is unlikely
that any observational study will be able to fully control
for these differences. Even if shown to be beneficial, the
full ‘costs’ (financial or other) of earlier cART must be
assessed. At least one randomised trial of earlier versus
deferred cART is underway [24] and it would be prudent
to wait for the results of this before changing guidelines.
Finally, whilst the decision to initiate cART is predo-
minantly based on an individual’s CD4 count, other
biomarkers [25-27] may also provide information about
an individual’s risk of clinical events; incorporation of
these biomarkers into the decision-making process
may further optimise the timing of cART in individual
patients.
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